1.18.18 - BGNE teamed up with CELG , receiving rights to market CELG's drugs in China for the next 10 years. BGNE acquired $750m from the offering which looks positive for new R&D of their drugs.
Further analysis: Failed breakout at the 120 range on weak . Choppy trading but may try another breakout if consolidation occurs within the 118-124 range. If consolidation and 118 range fails, this may fall to around the 104-108 range for a possible cup-and-handle set up.